Abstract
Purpose of review
The economic burden of diabetes in Japan is already serious and will become greater in the future. We review the economic impact of diabetes in Japan to examine viable options for mitigating its effects.
Recent findings
Medical costs for diabetes have been increasing by US $1 million annually, reaching US $11 million in 2009, of which US $7 million was accounted for by people aged 65 years or older. The quality of treatment of diabetes in Japan is higher than in other regions in the world. This can be more effective for achieving glycemic control, but is also more expensive compared with conventional treatment.
Summary
Because of the high cost of diabetes in Japan, a coordinated response is needed. Intervention trials for people with prediabetes aimed at preventing the occurrence of diabetes seem to be the most cost-effective method for lowering the medical costs of diabetes, rather than the use of new, expensive antidiabetic drugs in patients with established diabetes.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
International Diabetes Federation, editor. Diabetes Atlas. 6th ed: International Diabetes Federation; 2013.
• Health and Welfare Statistics Association. Kokumin Eisei no Doko (Trends in Nation’s Health, Japan). Health and Welfare Statistics Association: Tokyo; 2015 (in Japanese). This study provides annual national health trends in Japan.
Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Bärnighausen T, et al. The global economic burden of diabetes in adults aged 20-79 years: a cost-off-illness study. Lancet Diabetes Endocrinol. 2017;5:423–30.
Sagel JE. Cost-off-illness studies-A primer, RTI-UNC Center of Excellence in Health Promotion Economics; 2006.
Bagust A, Hopkinson PK, Maslove L, Currie CI. The project health care burden of type 2 diabetes in the UK from 2000 to 2060. Diabet Med. 2002;19(Suppl. 4):1–5.
Huang ES, Basu A, O’Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009;32:2225–9.
Vos T, Gross J, Begg S, Mann N. Projection of health care expenditure by disease: a case study from Australia. Brisbane, Australia: School of population Health, University of Queensland; 2007.
Waldeyer R, Brinks R, Rathmann W, Glani G, Icks A. Projection of the burden of type 2 diabetes mellitus in Germany: a demographic modelling approach to estimate the direct medical excess costs from 2010 to 2040. Diabet Med. 2013;30:999–1008.
Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29:855–62.
Javanbakht M, Mashayekhi A, Baradaran HR, Haghdoost A, Afshin A. Projection of diabetes population size and associated economic burden through 2030 in Iran: evidence from micro-simulation Markov model and Bayesian meta-analysis. PLoS One. 2015;10:e0132505.
Rowley WR, Bezold C. Creating public awareness: state 2025 diabetes forecasts. Popul Health Manag. 2012;15:194–200.
• Seuring T, Archangelidi O, Suhrcke. The economic costs of type 2 diabetes: A global systemic review. Pharmacoeconomics. 2015;33:811–31 This study reviews the societal cost of type 2 diabetes worldwide, estimated using direct and indirect costs based on previously published literature.
•• Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Bärnighausen T, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018;41:963–70 This study reports the GDP-relative economic burden in individuals aged 20–79 years using epidemiological and demographic data in 184 countries, projected from 2015 for 2030.
Health and Welfare Statistics Association. Kokumin Eisei no Doko (Trends in Nation’s Health, Japan). Tokyo: Health and Welfare Statistics Association; 2001. (in Japanese)
Kuriyama S, Tsuji I, Ohkubo T, Anzai Y, Takahashi K, Watanaeb Y, et al. Medical care expenditure associated with body mass index in Japan: the Ohsaki Study. Int J Obes Relat Metab Disord. 2002;26:1069–74.
Nakamura K, Okamura T, Kanda H, Hayakawa T, Okayama A, Ueshima H, et al. Medical costs of obese Japanese: a 10-year follow-up study of National Health Insurance in Shiga, Japan. Eur J Pub Health. 2007;17:424–9.
Shimoda M, Kaku K. Medical economy in the treatment of diabetes and its problems. Nippon Rinsho. 2012;70(Suppl. 5):663–6 (in Japanese).
Inada O. Medical costs in type 2 diabetes. Himan to Tounyobyo. 2009;8:672–5 (in Japanese).
DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr. 1994;125:177–88.
The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968–83.
Maruyama T. Medical costs in type 1 diabetes. Himan to Tounyobyo. 2009;8:670–1 (in Japanese).
• Kikuchi N, Tajima N, Ueki K, Yokoyama T, Ikegami H, Urakami T. Definition of complete insulin -dependent type 1 diabetes. Report of research grant from Ministry of Health, Labor and Welfare (H28-Junkanki-Ippan-006), 2018 (in Japanese). This report discusses the current economic status of diabetes treatment and management in 2018.
Aono S, Matsuura N, Ameiya S, Igrashi Y, Uchigata Y, Urakami T, et al. Epidemiological survey of social adjustment and living condition in patients with childhood onset insulin-dependent diabetes mellitus aged over 18 years. Tounyobyo. 1997;40:547–55 (in Japanese).
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–44.
Hisashige A. Prevention of diabetes and economic efficacy. Prog Med. 2005;25:80–5 (in Japanese).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Tatsuhiko Urakami, Remi Kuwabara, and Kei Yoshida declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Economics and Policy in Diabetes
Rights and permissions
About this article
Cite this article
Urakami, T., Kuwabara, R. & Yoshida, K. Economic Impact of Diabetes in Japan. Curr Diab Rep 19, 2 (2019). https://doi.org/10.1007/s11892-019-1122-9
Published:
DOI: https://doi.org/10.1007/s11892-019-1122-9